NCT06306456View on ClinicalTrials.gov

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Non-Small Cell Lung Cancer With EGFR Mutation
Interventions
DRUG

GH21

Oral, 15mg BIW/6mg QD

DRUG

Tagrisso

Oral, 80mg QD

Trial Locations (6)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

210008

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

230601

NOT_YET_RECRUITING

The Second Hospital of Anhui Medical University, Hefei

317099

RECRUITING

Taizhou Hospital of Zhejiang Province, Linhai

410031

RECRUITING

Hunan Cancer Hospital, Changsha

450000

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Suzhou Genhouse Bio Co., Ltd.

OTHER